一、关联交易基本情况 （一）关联交易履行的审议程序 2025年4月23日，公司召开第二届董事会审计委员会第七次会议通过了《关 于确认公司2024年度关联交易的议案》《关于预计公司2025年度日常关联交易的 议案》，出席会议的董事全部投票同意。 江苏集萃药康生物科技股份有限公司 关于确认2024年度关联交易及预计2025年度日常关 联交易公告 证券代码：688046 证券简称：药康生物 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次2024年度关联交易及预计2025年度日常关联交易事项均无需提交股 东大会审议。 江苏集萃药康生物科技股份有限公司（以下简称"公司"）2024年度与 关联方所发生的关联交易及2025年度与关联方预计发生的日常关联交易属于公 司从事生产经营活动的正常业务往来，符合正常商业逻辑及公平原则，在双方平 等协商达成的交易协议的基础上实施，交易条件及定价公允，不存在损害公司和 股东利益的情形。进行上述关联交易对公司主营业务不构成重大影响，公司不会 因该等关联交 ...

江苏集萃药康生物科技股份有限公司 董事会审计委员会对会计师事务所履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要求，江苏 集萃药康生物科技股份有限公司（以下简称"公司"）董事会审计委员会本着勤 勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对致同会计师事务 所（特殊普通合伙）（以下简称"致同所"）履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 会计师事务所名称：致同会计师事务所（特殊普通合伙） 成立日期：2011 年 12 月 22 日 注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 按照《审计业务约定书》，遵循《中国注册会计师审计准则》和其他执业规 范，结合公司 2024 年年报工作安排，致同所对公司 2024 年度财务报告及 2024 年 12 月 31 日的财务报告内部控制的有效性进行了审计，同时对公司募集资金存 放与实际使用情况、非经营性资金占用及其他关联资金往来等进行核查并出具了 专项报告。 经审计，致同所认 ...

公司代码：688046 公司简称：药康生物 江苏集萃药康生物科技股份有限公司 2024年度内部控制评价报告 江苏集萃药康生物科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于 ...

江苏集萃药康生物科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 证券代码：688046 证券简称：药康生物 公告编号：2025-033 （一） 股东大会类型和届次 2024年年度股东大会 召开日期时间：2025 年 5 月 28 日 10 点整 召开地点：南京市江北新区学府路 12 号 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 28 日 至2025 年 5 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年5月28日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 东大会召开当日的交易时间段，即 9:1 ...

证券代码：688046 证券简称：药康生物 公告编号：2025-032 江苏集萃药康生物科技股份有限公司 第二届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏集萃药康生物科技股份有限公司（以下简称"公司"）第二届监事会第十次 会议于 2025 年 4 月 24 日通过现场结合通讯的方式召开。本次会议的通知已于 2025 年 4 月 14 日送达全体监事。本次会议由监事会主席琚存祥先生召集并主持，应参会 监事 3 人，实际出席监事 3 人，公司部分高级管理人员列席了会议。本次会议的召 集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律法规及《江 苏集萃药康生物科技股份有限公司章程》（以下简称"《公司章程》"）的相关规定。 二、监事会会议审议情况 经与会监事认真审议，通过了以下议案： 1、审议通过《关于公司 2024 年年度报告及其摘要的议案》 监事会认为，公司 2024 年年度报告及摘要的编制和审议程序符合法律法规、《公 司章程》和公司内部管理制度的各 ...

证券代码：688046 证券简称：药康生物 公告编号：2025-031 江苏集萃药康生物科技股份有限公司 第二届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏集萃药康生物科技股份有限公司（以下简称"公司"）第二届董事会第十一 次会议于2025年4 月24日通过现场结合通讯的方式召开。本次会议的通知已于 2025 年 4 月 14 日送达全体董事。本次会议由董事长高翔先生召集并主持，应参会董事 9 人，实际出席董事 9 人，其中独立董事 3 人，公司监事、高级管理人员列席了会议。 本次会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等 法律法规及《江苏集萃药康生物科技股份有限公司章程》（以下简称"《公司章程》"） 的相关规定。 二、董事会会议审议情况 经与会董事认真审议，通过了以下议案： 1、审议通过《关于公司 2024 年年度报告及其摘要的议案》 董事会认为，公司 2024 年年度报告及摘要的编制和审议程序符合法律法规、《公 司章程》和公司内部 ...

证券代码：688046 证券简称：药康生物 公告编号：2025-021 江苏集萃药康生物科技股份有限公司 关于公司 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利人民币 1.10 元（含税），本次利润 分配不进行资本公积转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购专 用证券账户中股份为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本扣减公司回购专用证券账户 中的股份发生变动的，拟维持每股分配比例不变，相应调整分配总额，并将另行 公告具体调整情况。 公司未触及《上海证券交易所科创板股票上市规则》第 12.9.1 条第一款 第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经致同会计师事务所（特殊普通合伙）审计，江苏集萃药康生物科技股份有 限公司（以下简称"公司"）2024 年度实现归属于上市公司股东的净利润为 109,8 ...

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1.10 RMB per 10 shares, totaling approximately 44.82 million RMB (including tax) based on a share base of 407,410,638 shares[6]. - The total cash dividend for 2024, including interim distributions, amounts to approximately 57.07 million RMB, representing 51.97% of the net profit attributable to shareholders[6]. - The profit distribution plan has been approved by the board and requires further approval from the annual general meeting[7]. Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching $1.5 billion in Q3 2023[15]. - The company achieved total revenue of 686.84 million RMB in 2024, representing a year-on-year growth of 10.39%[38]. - Net profit attributable to shareholders decreased by 30.89% to 109.82 million RMB, while net profit excluding non-recurring gains and losses fell by 29.33% to 75.74 million RMB[38]. - The company's operating revenue for 2024 reached ¥686,837,009.60, representing a 10.39% increase compared to ¥622,186,991.12 in 2023[26]. - The net profit after deducting non-recurring gains and losses was ¥75,743,097.97, down 29.33% from ¥107,180,879.68 in 2023[26]. - The net cash flow from operating activities decreased by 22.52% to ¥90,314,259.53, primarily due to a reduction in government subsidies received[29]. - Basic earnings per share fell by 30.77% to ¥0.27 from ¥0.39 in the previous year[27]. Research and Development - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience and operational efficiency[15]. - The R&D expenditure as a percentage of operating revenue was 13.73%, down from 15.53% in 2023[28]. - The company achieved a total R&D investment of approximately ¥94.34 million, a decrease of 2.34% compared to the previous year, with R&D expenses accounting for 13.73% of total revenue[108]. - The company has developed a comprehensive gene editing platform, enhancing the efficiency of model creation and drug development processes[112]. - The company is focused on developing innovative mouse models using gene editing, stem cell technology, and phenotypic analysis, providing customized services for drug discovery and development[54]. Market Expansion and Strategy - Market expansion efforts are underway in Europe, with a target to increase market share by 5% by the end of 2024[15]. - The company announced a strategic acquisition of a smaller tech firm for $300 million to bolster its product offerings[15]. - The company is actively pursuing international expansion, with subsidiaries or offices established in the US, Europe, South Korea, and Japan, and its first overseas production facility set to open in San Diego in Q1 2024[83]. - The overseas business development team, consisting of approximately 40 members, has served over 500 international clients across more than 20 countries, indicating a low market penetration rate[190]. Operational Efficiency - The total operating expenses were reduced by 10%, amounting to $450 million, contributing to overall profitability[15]. - The company has implemented a 24h/48h/72h delivery system to improve customer response times and reduce transportation costs[39]. - The company has optimized its organizational structure for efficient operations, integrating headquarters and subsidiaries to streamline resource allocation and internal management[53]. - The company has established a comprehensive procurement system for materials and services, ensuring compliance and effective budget management[62]. Risk Management - The company has outlined various risks and countermeasures in its report, which investors should pay attention to[3]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has not violated decision-making procedures for external guarantees[11]. - The company faces risks related to the potential loss of core technical personnel, which could hinder R&D progress and operational efficiency[125]. Corporate Governance - The company has received a standard unqualified audit report from its accounting firm[5]. - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has not disclosed any special arrangements for corporate governance[8]. - The governance structure has been improved to ensure effective decision-making and compliance with relevant laws and regulations, enhancing operational efficiency[194]. Customer Engagement and Services - The company has established a complete sales channel in the domestic market, enhancing customer loyalty through value-added services and training programs[42]. - The company has launched a new online mouse shopping platform and a WeChat mini-program to improve customer ordering experience[43]. - The company plans to enhance its customer service and training systems to increase customer retention and expand its market share in second-tier cities by 2025[190]. Technological Advancements - The application of CRISPR/Cas9 technology has significantly improved the efficiency of mouse model creation, facilitating the expansion of application fields in both research and industrial sectors[84]. - The company has developed automated design systems for gene knockout, including tools for designing sgRNA and strategies for gene knockout, which enhance efficiency and reduce costs[88]. - The company has established a gene-engineered mouse model platform, an innovative drug screening and phenotypic analysis platform, and a germ-free mouse and microbiota colonization platform[88]. Financial Position - The company’s total assets at the end of the reporting period were 257,264.53 RMB, a slight decrease of 0.19% from the beginning of the period[142]. - Cash and cash equivalents increased to ¥701,371,554.95, representing 27.26% of total assets, up 25.21% from the previous period[161]. - The accounts receivable balance as of the reporting period end is CNY 383.95 million, with a significant increase of CNY 84.70 million compared to the previous year, primarily due to delayed payments from research clients[134].

Financial Performance - The company's operating revenue for Q1 2025 was ¥170,855,596.98, representing an increase of 8.76% compared to ¥157,087,264.43 in the same period last year[4]. - The net profit attributable to shareholders was ¥29,980,260.40, a slight increase of 1.70% from ¥29,479,404.17 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥25,108,916.52, reflecting a growth of 9.80% compared to ¥22,868,086.62 in the previous year[4]. - Total revenue for Q1 2025 reached ¥170,855,596.98, an increase of 8.8% compared to ¥157,087,264.43 in Q1 2024[16]. - Net profit for Q1 2025 was ¥29,980,260.40, slightly higher than ¥29,479,404.17 in Q1 2024, indicating a growth of 1.7%[17]. - Operating profit for Q1 2025 was ¥30,673,653.95, compared to ¥28,210,897.29 in Q1 2024, representing an increase of 8.7%[17]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,650,964,333.25, which is a 3.04% increase from ¥2,572,645,275.65 at the end of the previous year[5]. - The company's total current assets amounted to approximately ¥1.72 billion, slightly increasing from ¥1.71 billion as of December 31, 2024, reflecting a growth of 0.38%[13]. - The total non-current assets decreased from ¥1.01 billion to approximately ¥1.00 billion, indicating a decline of 1.1%[13]. - Total liabilities increased to ¥489,042,999.61 from ¥437,918,956.04, reflecting a rise of 11.7%[15]. - The company's equity attributable to shareholders rose to ¥2,161,921,333.64, compared to ¥2,134,726,319.61, an increase of 1.3%[15]. Cash Flow - The net cash flow from operating activities was -¥26,727,605.73, an improvement from -¥52,604,737.13 in the same period last year[4]. - Cash received from sales in Q1 2025 amounted to ¥125,542,405.66, a rise of 21.4% from ¥103,368,565.73 in Q1 2024[21]. - The net cash flow from operating activities was -$26.73 million, an improvement from -$52.60 million in the previous period[22]. - Cash inflow from investment activities totaled $375.41 million, down from $713.75 million year-over-year[22]. - The net cash flow from financing activities was $46.79 million, compared to a net outflow of -$16.04 million previously[23]. Research and Development - Research and development expenses totaled ¥20,170,418.65, down 12.31% from ¥23,002,751.52, with R&D expenses accounting for 11.81% of operating revenue, a decrease of 2.83 percentage points[5]. - Research and development expenses for Q1 2025 were ¥18,257,390.70, down from ¥23,002,751.52 in Q1 2024, indicating a decrease of 20.5%[17]. Inventory and Receivables - The company's accounts receivable increased from ¥350.81 million to ¥392.61 million, showing a growth of 11.9%[13]. - The company reported an increase in inventory from ¥54.20 million to ¥58.53 million, which is an increase of 8.5%[13]. Government Subsidies and Non-Recurring Items - The company received government subsidies amounting to ¥3,199,528.58, which are closely related to its normal operations[6]. - The total non-recurring gains and losses for the period amounted to ¥4,871,343.88 after tax adjustments[7]. Other Information - The total number of ordinary shareholders at the end of the reporting period was 5,832[9]. - The company has no significant new product launches or technological developments mentioned in the conference call[12]. - There are no plans for market expansion or mergers and acquisitions discussed during the call[12]. - The company did not provide specific future guidance or performance outlook in the conference call[12].

江苏集萃药康生物科技股份有限公司 独立董事 2024 年度述职报告 本人作为江苏集萃药康生物科技股份有限公司（以下简称"公司"）的独立 董事，严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董 事管理办法》《上海证券交易所科创板股票上市规则》等法律法规及《公司章程》 《独立董事工作制度》等规定，本着认真负责的态度，忠实勤勉的履行独立董事 的义务和职责，积极参加公司 2024 年召开的股东大会、董事会及董事会各专门 委员会等相关会议，认真审议董事会各项议案，对公司相关重大事项均发表了独 立意见，充分发挥了作为独立董事的专业优势及独立作用，现将 2024 年度主要 工作情况报告如下： 一、本人基本情况 （一）个人工作履历、专业背景以及兼职情况 杜鹃女士，1982年出生，中国国籍，无境外居留权，新加坡南洋理工大学金 融学专业硕士，注册会计师。杜鹃于2007年8月至2016年5月任中国证监会北京监 管局副主任科员、主任科员；2016年6月至2017年5月任高新普惠（北京）资产管 理有限公司副总经理；2017年6月至2020年5月任山西文化旅游产业投资管理有限 公司总经理；2020年7月至2022年12月 ...